Taysha Gene Therapies
TSHA
4.43
+0.04
+0.91%
Taysha Gene Therapies
US · TSHA
#3015 by market cap
Listed 2020
4.43
+0.04
+0.91%
Live - 5344 symbols - heartbeat 20s ago
· 2026-10-08 04:03
Pre-market
4.41
-0.45%
After-hours
4.43
0.00%
- Market cap
- 1.44B
- P/E (TTM)i
- -10.80
- P/Bi
- 3.73
- EPSi
- -0.34
- Div yieldi
- 0.00%
- 52W posi
- 20%
Reader sentiment
Are you bullish or bearish on TSHA?
Anonymous reader poll. Unscientific, not investment advice.
About Taysha Gene Therapies
Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company, which engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. It also develops multiple gene therapy platforms which include AAV9 Discovery, Novel Capsid, and AAV Redosing. The company was founded by Steven Gray, Berge Minassian, and R. A. Session II in 2019 and is headquartered in Dallas, TX.
- Founded
- 2019
- CEO
- Mr. Sean P. Nolan
- Employees
- 99
- Headquarters
- Dallas, Texas, United States of America
- Fiscal year end
- 12-31
- Website
- tayshagtx.com
Company profile
- Exchange
- US
- Symbol
- TSHA
- Market-cap rank
- #3015
- Listing date
- 2020-09-24
- Market cap
- 1.44B
- Float cap
- 1.03B
- Shares out
- 325.83M
- Float shares
- 232.62M
Sectors & themes
Quote time 2026-10-08 04:03:15 · For reference only, not investment advice and not tailored to your situation.